US Patent

US8475832 — Sublingual and buccal film compositions

Method of Use · Assigned to RB Pharmaceuticals Ltd · Expires 2030-03-26 · 4y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects self-supporting dosage forms for treating narcotic dependence, such as those used in Subutex, with sufficient buccal adhesion.

USPTO Abstract

The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

Drugs covered by this patent

Subutex (Buprenorphine Hydrochloride) · Indivior

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1411`	—	Subutex
`U-1411`	—	Subutex
`U-1411`	—	Subutex
`U-1411`	—	Subutex

Patent Metadata

Patent number: US8475832
Jurisdiction: US
Classification: Method of Use
Expires: 2030-03-26
Drug substance claim: No
Drug product claim: Yes
Assignee: RB Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.